FDA determines no cancer risk associated with Lantus - ONA
Links shared publicly online about this topic.
- 555total visits
FDA determines no cancer risk associated with Lantus - ONA
View full resource at oncologynurseadvisor.com
Tags: Diabetes Type 1 Medication, Diabetes Type 2 Medication, Diabetes Medication, Insulin, Cancer, FDA, Lantus, Sanofi-Aventis
Most Recently Shared on January 25, 2011 at 3:48 pm By:
FDA determines no cancer risk associated with Lantus http://goo.gl/fb/26fJr
Is Insulin Glargine (Lantus) Associated with Increased Risk of Cancer? | diabetes
diabeticlive.com — “Is Insulin Glargine (Lantus) Associated with Increased Risk of Cancer: Researchers conducted 11 in vitro studies on human and mice cells to determine whether” View full resource at diabeticlive.com
Most Recently Shared on August 31, 2011 at 1:11 pm By:
Is Insulin Glargine (Lantus) Associated with Increased Risk of Cancer? http://t.co/SS3k69G
FDA determines no cancer risk associated with Lantus - MPR
empr.com — “At this time, the FDA has concluded that Lantus (insulin glargine [recombinant], from sanofi-aventis) does not increase the risk of cancer.” View full resource at empr.com
Most Recently Shared on January 25, 2011 at 4:23 pm By:
MPR News: FDA determines no cancer risk associated with Lantus: At this time, the FDA has concluded that Lantus ... http://bit.ly/ftLZYS
Medical News: FDA Still Uncertain About Lantus Cancer Risk - in Endocrinology, Diabetes from MedPage Today
medpagetoday.com — “Eighteen months after starting a probe of potential cancer risks associated with insulin glargine (Lantus), the FDA still hasn't decided whether the concern is justified, the agency said.” View full resource at medpagetoday.com
Most Recently Shared on January 12, 2011 at 10:36 pm By:
FDA Still Uncertain About Lantus Cancer Risk http://bit.ly/exWVO3
Study to determine link between insulin glargine and cancer
news-medical.net — “Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may have driven the association.” View full resource at news-medical.net
Most Recently Shared on December 15, 2009 at 6:58 pm By:
Obesity News: Study to determine link between insulin glargine and cancer: Type 2 diabetes and obesity are linked... http://twurl.nl/bn1x0l
Advertisement
